N/A
Manufactured by Amphastar Pharmaceuticals, Inc.
13,146 FDA adverse event reports analyzed
Last updated: 2026-04-15
GLUCAGON is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amphastar Pharmaceuticals, Inc.. The most commonly reported adverse reactions for GLUCAGON include DRUG INEFFECTIVE, DYSPNOEA, ACUTE KIDNEY INJURY, HYPOTENSION, HYPOGLYCAEMIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLUCAGON.
Out of 3,941 classified reports for GLUCAGON:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,146 FDA FAERS reports that mention GLUCAGON. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DYSPNOEA, ACUTE KIDNEY INJURY, HYPOTENSION, HYPOGLYCAEMIA, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amphastar Pharmaceuticals, Inc. in connection with GLUCAGON. Always verify the specific product and NDC with your pharmacist.